066700 — THERAGEN ETEX CO Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapContrarian

Market Cap
KR₩101bn
Enterprise Value
KR₩124bn
Revenue
KR₩272bn

Annual income statement for THERAGEN ETEX CO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	166,567	190,769	216,470	249,625	271,590
Cost of Revenue
Gross Profit	61,175	77,868	100,668	125,981	141,013
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	175,648	179,746	204,906	231,786	261,421
Operating Profit	-9,081	11,023	11,564	17,839	10,169
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-12,676	13,855	32,747	-43,159	17,539
Provision for Income Taxes
Net Income After Taxes	-11,385	12,428	29,679	-40,141	11,746
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-11,854	9,561	26,211	-40,985	10,600
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-11,854	9,561	26,211	-40,985	10,600
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-333	249	850	-1,405	297
Dividends per Share